Loading...
•
Jun 30, 2023
Enliven Therapeutics Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023, and provided a business update.
Key Takeaways
Enliven Therapeutics reported a net loss of $16.7 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $277.9 million as of June 30, 2023. Patient enrollment and dose escalation continue to progress in the Phase 1 clinical trials of ELVN-001 and ELVN-002.
Continued progress of ELVN-001 and ELVN-002 through dose escalation in Phase 1 trials.
Initial proof of concept data for both ELVN-001 and ELVN-002 programs expected in 2024.
Selected a product candidate for the Company’s third program, with more information to be disclosed in 2024.
Closed the quarter with $277.9 million in cash, cash equivalents and marketable securities.